AI in Cancer Diagnostics Market Report 2026

The ai in cancer diagnostics market size has grown exponentially in recent years. It will grow from $0.79 billion in 2025 to $0.96 billion in 2026 at a compound annual growth rate (CAGR) of 20.2%. The growth in the historic period can be attributed to limited ai adoption in early diagnostic workflows, reliance on traditional imaging techniques, increasing cancer prevalence worldwide, rising demand for early detection solutions, expansion of diagnostic centers.

The ai in cancer diagnostics market size is expected to see rapid growth in the next few years. It will grow to $1.97 billion in 2030 at a compound annual growth rate (CAGR) of 19.9%. The growth in the forecast period can be attributed to advancements in deep learning and machine learning algorithms, growth of ai-powered imaging systems, increasing integration of predictive analytics in healthcare, rising investments in digital health technologies, collaboration between ai developers and medical institutions. Major trends in the forecast period include growing adoption of AI-based imaging and diagnostic tools, integration of predictive analytics in cancer screening, rising use of ai for tumor identification and classification, expansion of AI-driven monitoring and follow-up systems, increasing collaboration between hospitals and ai solution providers.

The rising incidence of cancer is anticipated to drive the expansion of the artificial intelligence (AI) in cancer diagnostics market in the coming years. Cancer encompasses a group of diseases characterized by uncontrolled cell growth that can invade or spread to other parts of the body. The adoption of AI in cancer care focuses on improving efficiency, precision, and personalized treatment approaches, thereby enhancing patient outcomes. For instance, in May 2024, the National Cancer Institute, a U.S.-based government agency, reported that around 2 million new cancer cases are projected to be diagnosed in the United States in 2024, with more than 611,000 deaths expected. Globally, new cancer cases are forecasted to reach 29.9 million by 2040, while cancer-related deaths are projected to rise to 15.3 million. Therefore, the growing prevalence of cancer is fueling the growth of the AI in cancer diagnostics market.

Major companies operating in the AI in cancer diagnostics market are witnessing substantial growth driven by advancements in AI-enabled digital pathology solutions for cancer diagnosis. These solutions involve the application of AI algorithms to identify cancer and other diagnostic markers across various tissue types, enabling accurate and timely diagnoses, supporting case prioritization, and ensuring consistent diagnostic outcomes. For instance, in November 2023, Dedalus and Ibex Medical Analytics, a Europe-based healthcare software provider, introduced an integrated end-to-end AI-powered digital pathology solution for cancer diagnosis across Europe. The solution is designed to enhance diagnostic accuracy, offer AI-based decision support, simplify reporting processes, improve laboratory efficiency, and boost diagnostic confidence.

In December 2023, Lunit, a South Korea-based AI company, acquired Volpara for $193 million. This acquisition is expected to strengthen the combined company’s position as a major player in AI-driven cancer diagnostics, particularly in the U.S. market, supported by Volpara’s presence in more than 2,000 medical facilities across the country and its database of over 100 million high-quality mammogram images. The transaction is subject to approval from Volpara’s shareholders and the New Zealand High Court. Volpara is a New Zealand-based company specializing in AI-powered software for personalized screening and early detection of breast cancer.

Major companies operating in the ai in cancer diagnostics market are Microsoft Corporation, IBM Corporation, Verily Life Sciences LLC, Tempus Labs Inc, Guardant Health Inc, Lunit Inc, Paige AI Inc, Viz.ai Inc, Enlitic Inc, Ibex Medical Analytics Ltd, Kheiron Medical Technologies Limited, CureMetrix Inc, CancerIQ Inc, MultiplAI Health Inc, Freenome Holdings Inc, SkinVision B V, Owkin Inc, Imagen Technologies Inc, Cyrcadia Health Inc, Oncora Medical Inc, Xilis Inc.

North America was the largest region in the artificial intelligence in cancer diagnostics market in 2025. The regions covered in the ai in cancer diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the ai in cancer diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the AI in cancer diagnostics market by increasing costs of imported imaging hardware, specialized software solutions, and diagnostic devices, affecting adoption rates in hospitals and diagnostic centers. Segments like AI-powered imaging systems and deep learning software are particularly impacted, especially in regions such as North America, Europe, and Asia-Pacific. While tariffs raise operational costs and delay deployments, they also promote local manufacturing of AI diagnostic solutions and encourage regional innovation in software development and integration services.

The ai in cancer diagnostics market research report is one of a series of new reports that provides ai in cancer diagnostics market statistics, including ai in cancer diagnostics industry global market size, regional shares, competitors with a ai in cancer diagnostics market share, detailed ai in cancer diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the ai in cancer diagnostics industry. This ai in cancer diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

AI in cancer diagnostics involves the application of artificial intelligence methods, including machine learning and deep learning, to examine medical images, genomic information, and patient records in order to support the early identification, diagnosis, and outcome prediction of cancer. These technologies are capable of detecting patterns and irregularities in complex datasets that may not be easily noticeable to humans, thereby enhancing the accuracy and speed of diagnostic processes.

The key components of AI in cancer diagnostics include software solutions, hardware, and services. Software solutions encompass the use of AI and machine learning tools to enhance the precision and effectiveness of cancer detection, prognosis assessment, and treatment decision-making. The technology is applied across multiple cancer types such as breast cancer, lung cancer, brain tumors, skin cancer, cervical cancer, prostate cancer, colorectal cancer, and others. These solutions are utilized for a range of purposes including screening and diagnosis, tumor detection, and disease monitoring, and are adopted by various end users such as hospitals, diagnostic laboratories, medical research institutions, and contract research organizations.

AI in the cancer diagnostics market consists of revenues earned by entities by providing services such as early detection and screening, image analysis and interpretation, predictive analytics, and treatment planning. The market value includes the value of related goods sold by the service provider or included within the service offering. The AI in Cancer Diagnostics market also consists of sales of medical imaging devices, pathology analysis systems, genomic sequencing equipment, and patient monitoring devices that are used in providing services. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.